Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells define commitment to apoptosis
نویسندگان
چکیده
Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT Division of Hematology and Medical Oncology, Oregon Heath & Science University, Portland, OR Knight Cancer Institute, Portland, OR Howard Hughes Medical Institute, Portland, OR Department of Physiology and Pharmacology, Oregon Health & Science University, Portland, OR Bioanalytical Shared Resource/Pharmacokinetics Core, Oregon Health & Science University, Portland, OR Life Technologies, Madison, WI BD Biosciences, San Diego, CA Department of Cell and Developmental Biology, Oregon Health & Science University, Portland, OR * These authors contributed equally to this work.
منابع مشابه
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
The imatinib paradigm in chronic myelogenous leukemia (CML) established continuous BCR-ABL inhibition as a design principle for ABL tyrosine kinase inhibitors (TKI). However, clinical responses seen in patients treated with the ABL TKI dasatinib despite its much shorter plasma half-life and the apparent rapid restoration of BCR-ABL signaling activity following once-daily dosing suggested acute,...
متن کاملAnalysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملStudy of STAT3 Expression in Different Phases of Patients with Chronic Myeloid Leukemia
Background and Aim: Chronic myeloid leukemia(CML) is a clonal myeloproliferative disease, characterized by BCR/ABL translocation. Using tyrosine kinase inhibitors such as Imatinib, treatment for this disease has progressed remarkably. However, resistance to tyrosine kinase inhibitor is a major obstacle. Signal transducer and activator of transcription 3(STAT3) is an important transcription fact...
متن کاملBcr-abl Silencing by Specific Small-Interference RNA Expression Vector as a Potential Treatment for Chronic Myeloid Leukemia
Background: RNA interference (RNAi) is the mechanism of gene silencing-mediated messenger RNA degradation by small interference RNA (siRNA), which becomes a powerful tool for in vivo research, especially in the areas of cancer. In this research, the potential use of an expression vector as a specific siRNA producing tool for silencing of Bcr-abl in K562 cell line has been investigated. Methods:...
متن کاملLoss of SYK and LYN Tyrosine Kinase Expression Impair Ponatinib-Induced Apoptosis in K562 Cells
Targeting the tyrosine kinase activity of BCR-ABL is the gold standard strategy in Chronic Myeloid Leukemia (CML) for the last decade. Whereas inhibitors of BCR-ABL tyrosine kinase are now used in frontline therapy for CML, third generation inhibitors of BCR-ABL tyrosine kinase such as ponatinib has been developed for the treatment of BCRABL resistant mutants. In the current study, we generated...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013